The Les Turner ALS Foundation is excited to announce nearly $1 million to be funded in 2022 for new research grants and clinic and endowment support to the Les Turner ALS Center at Northwestern Medicine! These discoveries would not have …
Response to NINDS Request for Information on ALS Strategic Plan
February 11, 2022 Dear NINDS, As we set our sights on shaping the strategic future of ALS research, we thank you for the opportunity to identify key research and priorities at NIH and beyond. We also recognize …
ALS News Today: New Directions in Research, Care Focus of Les Turner ALS Symposium
By Marta Figueiredo PhD | November 18, 2021 Recent findings and ongoing efforts to more fully understand the underlying molecular mechanisms of amyotrophic lateral sclerosis (ALS), and to identify new and better ways of helping patients were discussed at the 11th Annual Les Turner Symposium …
Les Turner ALS Symposium Celebrates Advances in Research and Patient Care
BY MELISSA ROHMAN ON NOV 4, 2021 Northwestern scientists and clinicians demonstrated their continued commitment to advancing knowledge and therapies for amyotrophic lateral sclerosis (ALS) during the 11th annual Les Turner Symposium on ALS. The virtual, daylong symposium featured scientific presentations highlighting the molecular …
Biogen Briefing Notes – Scientific Advisory Council (SAC)
The following note is being passed along from the Board of Directors of the International Alliance of ALS/MND Associations… The Board of Directors of the International Alliance of ALS/MND Associations is pleased to provide information for Member Associations in the …
AMX0035 May Slow ALS Progression and Extend Life
On September 15, Amylyx Pharmaceuticals announced its intention to submit a New Drug Application to the FDA for AMX0035 for the treatment of ALS. If the New Drug Application is successful, AMX0035 would be only the third drug approved by …
Chicago Virtual NEALS ALS Clinical Research Learning Institute
The first-ever 2021 Chicago Virtual NEALS ALS Clinical Research Learning Institute (CRLI) was a great success! Thank you to all the patients, caregivers, and surviving family members who joined for the annual two-day program. Now, all attendees are certified as …
Research May Lead to New Ways to Combat ALS
Because we live in a changing environment, our survival and function depend on adapting to novel, potentially stressful, conditions. Is our ability to adapt to changing conditions fixed or is it possible to enhance our ability to tolerate a stressful …
Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation
Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
Today was a tough call for the ALS community, but not entirely disheartening. BrainStorm released the topline results this morning (November 17) from its Phase 3 trial for NurOwn® showing it did not meet statistical significance in its primary efficacy …
